Keyword: AstraZeneca

Phase 1 data for PhaseBio's Brilinta reversal agent showed the drug quickly reversed the effects of Brilinta without causing serious side effects.

ExcepGen believes its approach could speed up discovery and even come up with protein targets previously thought to be undruggable.

The deal will see AstraZeneca pay $20 million to collaborate with Seres and test SER-401 in combination with its oncology assets.

Compugen is “streamlining” its R&D operations to pare down costs and ensure it can afford the phase 1 study of its lead asset, an anti-PVRIG antibody.

The PD-L1 combination trials led the clear out, and the immuno-oncology drugs tested in those studies feature heavily in the earlier-phase cull.

CMO Sean Bohen and I-O head David Berman are leaving AstraZeneca, while Roche's Omar Khwaja and Pearl Huang land at new biotechs.

Bloomberg reports that Sean Bohen, CMO and EVP of global medicines development, is out the door at AstraZeneca.

Baselga to helm AstraZeneca’s cancer R&D; ex-Novartis exec joins UroGen; Roche exec moves to Genevant; and Immunocore poaches from AZ’s biologics arm.

Major changes are afoot at AstraZeneca as it shakes up its research structure with new units, new names and big moves.

Nearly a year after its former chief Eliot Forster stepped down, Immunocore has a new full-time CEO in Medimmune’s president Bahija Jallal.